Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

470
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
470
Prodrugs01:30

Prodrugs

2.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
2.7K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

428
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
428
Drug Elimination by Renal Route: Tubular Secretion01:15

Drug Elimination by Renal Route: Tubular Secretion

2.5K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.5K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

789
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
789

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of APOL1-Associated Pregnancy Complications on Kidney Disease Phenotypes in a HIV-Associated Nephropathy Mouse Model.

Kidney360·2026
Same author

A new brake on podocyte injury: ATOH8 meets TGF-β.

American journal of physiology. Renal physiology·2026
Same author

Inflammatory Stromal Aging in Ulcerative Colitis and Colitis-Associated Cancer.

bioRxiv : the preprint server for biology·2026
Same author

Discovery and Cryo-EM-Guided Development of a Neuropilin-2-Binding Aptamer for Receptor Antagonism.

Journal of the American Chemical Society·2026
Same author

High-throughput, organ-scale 3D tubule tracking using TubuleMAP.

bioRxiv : the preprint server for biology·2026
Same author

A single cell atlas of mouse podocytes upon injury identifies kidney zone-dependent responses.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 27, 2025

Author Spotlight: Generation of Patient-Derived Podocytes from Skin Biopsies
08:52

Author Spotlight: Generation of Patient-Derived Podocytes from Skin Biopsies

Published on: May 26, 2023

2.2K

Repurposing drugs for diseases associated with podocyte dysfunction.

Stuart J Shankland1, J Ashley Jefferson2, Oliver Wessely3

  • 1Division of Nephrology, University of Washington, Seattle, Washington, USA; Institute for Stem Cell & Regenerative Medicine, University of Washington, Seattle, Washington, USA.

Kidney International
|June 8, 2023
PubMed
Summary
This summary is machine-generated.

Repurposing existing FDA-approved drugs offers a promising strategy to treat progressive podocyte disorders and chronic kidney disease, potentially reducing side effects and costs associated with novel therapies.

Keywords:
FDAglomeruluskidneypodocytepodocytopathiestherapeutics

More Related Videos

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

489
Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
08:06

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions

Published on: July 2, 2020

4.7K

Related Experiment Videos

Last Updated: Jul 27, 2025

Author Spotlight: Generation of Patient-Derived Podocytes from Skin Biopsies
08:52

Author Spotlight: Generation of Patient-Derived Podocytes from Skin Biopsies

Published on: May 26, 2023

2.2K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

489
Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
08:06

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions

Published on: July 2, 2020

4.7K

Area of Science:

  • Nephrology
  • Pharmacology
  • Molecular Biology

Background:

  • Podocyte disorders are progressive, leading to chronic kidney disease and failure.
  • Current treatments involve nonspecific immunosuppressants with significant side effects.
  • Recent advances illuminate molecular mechanisms of podocyte injury.

Approach:

  • Investigate repurposing FDA-approved therapeutics for podocyte disorders.
  • Leverage existing safety profiles and completed drug development.
  • Reduce costs and timelines for alternative indications.

Key Points:

  • Therapeutic repurposing offers known safety and established development.
  • Identifies mechanistic targets for approved drugs in podocyte damage.
  • Explores cost-effective strategies for treating kidney diseases.

Conclusions:

  • Repurposing approved drugs presents a viable strategy for podocyte disorders.
  • Addresses limitations of current nonspecific immunosuppressive therapies.
  • Accelerates development of novel treatments for chronic kidney disease.